- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer.
Showing 1–12 of 76 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
---|---|---|---|---|---|---|---|---|---|---|
FRɑ |
Antibody-drug conjugate (ADC) |
Elahere® |
5 mg/mL |
– |
2 mg |
tba |
tba |
1.817,00 € |
||
CCR4 |
Monoclonal Antibody |
Poteligeo® |
4 mg/mL |
– |
0,5 mg |
-80 °C |
09/2023 |
312,30 € |
||
CD20 , CD3 |
Bispecific Antibody |
Lunsumio® |
1 mg/mL |
– |
0.05 mg |
tba |
tba |
316,00 € |
||
CD20 |
Monoclonal Antibody |
Gazyvaro® |
25 mg/mL |
– |
6 mg |
-80°C |
06/2019 |
279,90 € |
||
CD20 |
Monoclonal Antibody |
Gazyvaro® |
25 mg/mL |
– |
6 mg |
-80°C |
08/2019 |
279,90 € |
||
EGFR |
Monoclonal Antibody |
Vectibix® |
20 mg/mL |
– |
2 mg |
-80 °C |
02/2025 |
230,00 € |
||
HER2 |
Monoclonal Antibody |
Perjeta® |
30 mg/mL |
yes |
6 mg |
-80°C |
11/2020 |
419,40 € |
||
HER2 |
Monoclonal Antibody |
Phesgo® |
60 mg/mL |
– |
12 mg |
tba |
tba |
717,00 € |
||
CD79b |
Antibody-drug conjugate (ADC) |
Polivy® |
20 mg/mL |
– |
1 mg |
-80 °C |
06/2024 |
536,00 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
03/2018 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
06/2018 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
08/2018 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
01/2019 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
12/2019 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
06/2020 |
182,70 € |
||
CD20 |
Biosimilar , Monoclonal Antibody |
Ruxience® |
10 mg/mL |
– |
2 mg |
tba |
tba |
196,00 € |
||
CD20 |
Biosimilar , Monoclonal Antibody |
Truxima® |
10 mg/mL |
– |
2 mg |
tba |
tba |
234,00 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
05/2018 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
09/2018 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
12/2018 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
02/2019 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
02/2019 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
08/2019 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
12/2019 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
07/2021 |
126,90 € |
||
CD20 |
Biosimilar , Monoclonal Antibody |
Rixathon® |
10 mg/mL |
– |
2 mg |
-80 °C |
03/2026 |
311,00 € |
||
Trop-2-directed ADC |
Antibody-drug conjugate (ADC) |
Trodelvy® |
10 mg/mL |
– |
4 mg |
-80°C |
08/2025 |
299,00 € |
||
CD3 , TCR targeting domain |
Bispecific fusion protein |
Kimmtrak® |
0,2 mg/mL |
– |
0.01 mg |
tba |
tba |
4.602,00 € |
||
B cell maturation antigen , CD3 |
Bispecific Antibody |
Tecvayli® |
10 mg/mL |
– |
0,5 mg |
tba |
tba |
303,00 € |
||
Tissue factor (TF) |
Antibody-drug conjugate (ADC) |
Tivdak® |
10 mg/mL |
– |
1 mg |
tba |
tba |
1.665,00 € |
Evidentic GmbH
Martin-Buber-Str. 10
14163 Berlin